半乳糖凝集素3在慢性心力衰竭中的诊断价值

Abstract
Figure/Table
References
Related Citation (4)

Download: PDF (860 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective： To analyze the correlation between serum galectin-3 (Gal-3) with heart function, left ventricular ejection fraction (LVEF) and Btype natriuretic peptide (BNP) in chronic heart failure (CHF), and evaluate the value of Gal3 in diagnosis of CHF. Methods： A total of 200 patients with CHF were divided into three groups according to their heart function: NYHA class Ⅱ, class Ⅲ and class Ⅳ; and 200 normal subjects enrolled as control group. Clinic parameters, including triacylglycerol, total cholesterol, blood urea nitrogen (BUN), serum creatinine(SCr), glycosylated hemoglobin (HbA1c), BNP and Gal3 were determined and echocardiography was tested for each participant. Results： Compared with control group, Gal3 levels in CHF group were significantly elevated \[(34.88±11.86)μg/L vs.(15.67±6.20) μg/L, P<0.01\]. With the deterioration of NYHA heart function in CHF group, concentration of serum Gal-3 increased gradually(P<0.01). The correlation analysis showed that the serum Gal-3 concentration was positively related to BNP (r=0.504,P<0.01), NYHA heart function (r=0.756,P<0.01) and negatively related to LVEF (r=-0.678, P<0.01). The receiver-operating characteristic curve (ROC) analysis showed that Gal-3 could be a predictor of CHF with an area under the curve (AUC) 0.792 (P<0.01) and the cutoff point for Gal3 was 18 μg/L. Conclusion： The serum Gal-3 concentration in CHF group was significantly elevated, positively related to NYHA heart function and could be used as diagnostic criteria of CHF.

Received: 26 June 2016

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://zzs.ujs.edu.cn/xbyxb/EN/ OR http://zzs.ujs.edu.cn/xbyxb/EN/Y2016/V26/I05/440

［1］Henderson NC, Sethi T. The regulation of inflammation by galectin3\[J\]. Immunol Rev, 2009,230（1）:160-171.
［2］Liu FT, Rabinovich GA. Galectins as modulators of tumour progression\[J\]. Nat Rev Cancer,2005,5（1）: 29-41.
［3］Falcone C, Luclbello S, Mazzuchelli I, et al. Galectin3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome \[J\]. Int J Immunopathol Pharmacol, 2011, 24（4）:905-913.
［4］Pugliese G, Pricci F, Leto G, et al. The diabetic milieu modulates the advanced glycation end productreceptor complex in the mesangium by inducing or upregulation galectin3 expression\[J\]. Diabetes,2000,49（7）:1249-1257.
［5］Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin3 regulates myofibroblast activation and hepatic fibrosis \[J\]. PNAS, 2006, 103（13）: 5060-5065.
［6］de Boer RA, Voors AA, Muntendam P, et al. Galectin3: a novel mediator of heart failure development and progression \[J\]. Eur J Heart Fail, 2009, 11（9）:811-817.
［7］Travers JG, Kamal FA, Robbins J, et al. Cardiac fibrosis: The fibroblast awakens\[J\]. Circ Res,2016,118（6）:1021-1040.
［8］中华医学会心血管病学分会.中国心力衰竭诊断和治疗指南2014\[J\].中华心血管病杂志，2014,4（2）:98-122.
［9］Malhotra R, Bakken K, D’Elia E, et al. Cardiopulmonary exercise testing in heart failure\[J\]. JACC Heart Fail, 2016, 4（8）:607-616.
［10］Troughton R, Michael Felker G, Januzzi JL Jr. Natriuretic peptideguided heart failure management\[J\]. Eur Heart J, 2014,35（1）:16-24.［11］Wang L, Friess H, Zhu Z, et al. Galectin1 and galectin3 in chronic pancreatitis\[J\]. Lab Invest，2000, 80（8）:1233-1241.
［12］Nishi Y, Sano H, Kawashima T, et al. Role of galectin3 in human pulmonary fibrosis\[J\]. Allergol Int, 2007, 56（1）:57-65.
［13］Sharma UC, Pokharel S, van Barkel TJ, et al. Galectin3 marks activated macrophages in failureprone hypertrophied hearts and contributes to cardiac dysfunction\[J\]. Circulation, 2004, 110（19）:3121-3128.
［14］Yu L, Ruifrok WP, Meissner M, et al. Genetic and pharmacological inhibition of galectin3 prevents cardiac remodeling by interfering with myocardial fibrogenesis\[J\]. Circ Heart Fail, 2013, 6（1）:107-117.
［15］van Kimmenade RR, Januzzi JL, Ellinor PT, et al. Utility of aminoterminal probrain natriuretic peptide, galectin3, and apelin for the evalution of patients with acute heart failure\[J\]. J Am Coll Cardiol, 2006,48（6）:1217-1224.
［16］Lok DJ, Lok SI, BrugginkAndré de la Porte PW, et al. Galectin3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure\[J\]. Clin Res Cardiol,2013, 102（2）:103-110.
［17］Yao Y, Shen D, Chen R, et al. Galectin3 predicts left ventricular remodeling of hypertension\[J\]. J Clin Hypertens, 2016,18（6）:506-511.
［18］EudeLe Parco, Gendronneau G, Dang T, et al. Genetic assessment of the importance of galectin3 in cancer initiation, progression, and dissemination in mice\[J\]. Glycobiology, 2009, 19（1）: 68-75.